US 11,986,511 B2
Use of a VEGF antagonist to treat angiogenic eye disorders
George D. Yancopoulos, Yorktown Heights, NY (US)
Assigned to REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed by REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed on Oct. 16, 2020, as Appl. No. 17/072,417.
Application 17/072,417 is a continuation of application No. 16/397,267, filed on Apr. 29, 2019, granted, now 10,888,601, issued on Jan. 12, 2021.
Application 16/397,267 is a continuation of application No. 16/159,282, filed on Oct. 12, 2018, granted, now 10,828,345, issued on Nov. 10, 2020.
Application 16/159,282 is a continuation of application No. 15/471,506, filed on Mar. 28, 2017, granted, now 10,130,681, issued on Nov. 20, 2018.
Application 15/471,506 is a continuation of application No. 14/972,560, filed on Dec. 17, 2015, granted, now 9,669,069, issued on Jun. 6, 2017.
Application 14/972,560 is a continuation of application No. 13/940,370, filed on Jul. 12, 2013, granted, now 9,254,338, issued on Feb. 9, 2016.
Application 13/940,370 is a continuation in part of application No. PCT/US2012/020855, filed on Jan. 11, 2012.
Claims priority of provisional application 61/432,245, filed on Jan. 13, 2011.
Claims priority of provisional application 61/434,836, filed on Jan. 21, 2011.
Claims priority of provisional application 61/561,957, filed on Nov. 21, 2011.
Prior Publication US 2021/0023173 A1, Jan. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61K 9/00 (2006.01); C07K 14/71 (2006.01); C07K 16/22 (2006.01); C07K 19/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 38/179 (2013.01) [A61K 9/0048 (2013.01); C07K 14/71 (2013.01); C07K 16/22 (2013.01); A61K 2039/505 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01)] 23 Claims
 
1. A method for treating macular edema following retinal vein occlusion in a patient in need thereof comprising administering to the patient, by intravitreal injection, a single initial dose of 2 mg aflibercept, followed by five secondary doses of 2 mg aflibercept, followed by one or more tertiary doses of 2 mg of aflibercept;
wherein each secondary dose is administered to the patient approximately 4 weeks following the immediately preceding dose;
wherein each tertiary dose is administered on an as needed or pro re nata (PRN) basis, based on visual or anatomic outcomes as assessed by a qualified medical professional; and
wherein the patient achieves a gain in visual acuity of at least 15 letters, compared to baseline by 52 weeks following the initial dose, as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart.